Rare Neurological Disease Treatment Market: North America to Remain Dominant in the Market: Global Industry Analysis (2012 - 2016) & Opportunity Assessment (2017 - 2026)
- REP-GB-6445
- 2018-03-14
- Category: Healthcare, Pharmaceuticals and Medical devices
- 170 Pages
- Format:
Majority of rare diseases at present have none or little effective procedures of diagnosis & treatment, which can be partly attributed to absence of funding toward researches on rare disease pathogenesis and lack of representative patients. Rare neurological disease are among major types of rare diseases with ineffective diagnoses and treatment options. According to WHO, 1 in 10 individuals are expected to be diagnosed with rare neurological disorder in their lifetime. Brain diseases are considered to be one of the major determinants of the neurological disease prevalence worldwide, with early intervention being the only key to prevent or curtail long-term morbidity and relevant healthcare costs.
However, diagnosis of rare neurological diseases entails several barricades including lack of intelligence and awareness about such diseases within the common medical community. This has further resulted into delayed diagnosis, and sometimes misdiagnosis, as highlighted in the book about rare diseases compiled by European Organization for Rare Diseases (EURORDIS), co-funded by European Commission. According to the publication, patients suffering from rare neurological diseases experience challenges in accessing treatment services on the coattails of lack of referral.
Spreading awareness about these diseases along with increasing their visibility are key initiatives taken by various governments worldwide for speeding up diagnostic processes and provide affected families with access to proper counselling and treatment options.
A recently published report of Future Market Insights foresees the global rare neurological disease treatment market to record a spectacular growth between the period 2017 and 2026. Revenues from treatment of rare neurological disorders worldwide are poised to surpass US$ 12,000 Mn by 2026-end.
North America to Remain Largest Revenue Contributor to the Market
In North America, rare neurological conditions are considered to a major healthcare concern, although fewer individuals are currently affected by the disease. Complexity of these diseases, along with their inadequacy in treatment options have led to disproportionate share of spending in healthcare. Drug companies in North America are conducting robust researches in rare diseases, however they face difficulties related to cost of treatment development related to small or geographically dispersed populations.
Government and healthcare institutes in North America are therefore collaborating to develop a robust research network, in order to facilitate data sharing, enrollment in trials & studies, and advancement in rare diseases. This will further influence the rare neurological disease treatment market in North America. The report estimates North America to remain the largest revenue contributor to the market.
Discrepancies in R&D Funding for Rare Neurological Disease Linked with Shortage in Healthcare Provision
Management of rare neurological diseases and provision of effective therapies represent an economic and social burden on several nations. Treatment options for patients affected with rare neurological conditions continue to be limited. Discrepancies in funding for R&D associated with treatment & prevention of these diseases is mainly linked with shortfall in the healthcare provision that reflects both shortage of material sources and suboptimal training exercises of clinicians apropos brain disorders.
Although there have been notable advancements in treatment of rare neurological diseases, these are not completely curative. Governments across the globe are therefore making significant improvements in their healthcare systems to render their management to be multidisciplinary, holistic, and to include supportive and palliative care. Establishing centers of expertise, which specialize in diagnosis, treatment & care of patients affected from rare neurological diseases, is a key focus area for most of the developed and developing countries across the globe.
Key players fuelling growth of the global rare neurological disease treatment market, as identified by the report, include Pfizer Inc., Allergan Plc, Novartis AG, Bayer Aktiengesellschaft, Medtronic Plc, Sanofi, Johnson & Johnson, and Teva Pharmaceutical Industries Limited.
Declining blockbuster drugs are leading pharmaceutical industries to keenly investigate new avenues of research and development. Several drug manufacturers, incentivized by Orphan Drug Act, are developing new drug formulations pertaining to the treatment of rare diseases, in a bid to introduce new treatment options to the market. This has further influenced the development of drugs for treatment of rare neurological disorders. Regulatory advantages including breakthrough designations, reduced fees & tax incentives, and longer market exclusivity, are encouraging investments in the R&D of drugs apropos to rare neurological diseases.
A new report of Future Market Insights offers forecast and analysis on the rare neurological disease treatment market on a global level. The report delivers actual data related to the market for the historical period (2012-2016) along with an estimated intelligence on the market for the forecast period (2017-2026). The information is presented in terms of value (US$ Mn). Macroeconomic indicators coupled with an outlook on the rare neurological disease treatment demand pattern around the world have also been encompassed by the report. The report further imparts key drivers and restraints for the global rare neurological disease treatment market, and their impact on regional segments included over the forecast period.
Report Structure
The executive summary chapter, which initiates the report, offers key market dynamics and numbers associated with the global rare neurological disease treatment market, along with key research findings related to the market segments comprised. The market numbers included in this chapter are a blend of compound annual growth rates, market shares, revenues, and volume sales.
A concise introduction to the rare neurological disease treatment market is offered in the chapter succeeding the executive summary, along with a formal definition of “rare neurological disease treatment”. Elaboration of the market dynamics that include future prospects, growth limitations & drivers, and trends has been delivered in the chapters subsequent to the overview. These chapters also inundate insights apropos to bottom line of enterprises in detail, along with the fiscal stimulus and the global economy.
Market Taxonomy
|
Region |
Indication |
Drug Type |
Mode of Administration |
Distribution Channel |
|---|---|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Competition Landscape
A complete package of intelligence on leading participants supporting expansion of the global rare neurological disease treatment market has been offered in the concluding chapter of this analytical research report. This chapter elucidates the competition landscape of the global market for rare neurological disease treatment, providing information on key strategy implementations of the market players, their product overview, key development, company overview, and key financials. A SWOT analysis on each market players has been provided in this chapter of the report.
The geographical spread of the market players included, along with their future growth plans, intended mergers & acquisitions, overall revenues, and market shares are elaborated in detail in this chapter. The report has employed an intensity map for portraying key market players located across geographies.
Research Methodology
Credibility of researched statistics & data is backed by a unique research methodology used by analysts at FMI, ensuring high accuracy. This research report on global rare neurological disease treatment market can assist readers in acquiring detailed insights on several aspects that govern the market across the regional segments contained in the report. The report readers can use slated strategies to tap the vital revenue pockets, thereby gaining benefits over intensifying competition prevailing in the market. Intelligence presented in this report has been scrutinized & monitored thoroughly by FMI’s industry experts. The figures and numbers offered by the report are validated by the analysts for facilitating strategic decision making for market players.
Rare Neurological Disease Treatment Market Reports - Table of Contents
1. Global Economic Outlook
2. Global Rare Neurological Disease Treatment Market - Executive Summary
3. Global Rare Neurological Disease Treatment Market Overview
3.1. Introduction
3.1.1. Global Rare Neurological Disease Treatment Market Taxonomy
3.1.2. Global Rare Neurological Disease Treatment Market Definition
3.2. Global Rare Neurological Disease Treatment Market Size (US$ Mn) and Forecast, 2012-2026
3.2.1. Global Rare Neurological Disease Treatment Market Y-o-Y Growth
3.3. Global Rare Neurological Disease Treatment Market Dynamics
3.4. Supply Chain
3.5. Cost Structure
3.6. USA, EU & Japan Orphan Designations per Year & Cumulative (1983 – 2016)
3.7. Worldwide Top 20 Orphan Drug Manufacturers (2016 – 2022)
3.8. Wheel of Fortune
3.9. Rare Disease Key Regulations
3.9.1. Rare Disease Key Regulations: North America
3.9.2. Rare Disease Key Regulations: Latin America
3.9.3. Rare Disease Key Regulations: Europe
3.9.4. Rare Disease Key Regulations: Asia Pacific
3.9.5. Rare Disease Key Regulations: Middle East & Africa
3.10. Forecast Scenario
3.11. PEST Analysis
3.12. Porte's Five Forces Analysis
3.13. Market Positioning and Behavioral Assessment
3.14. Investment Feasibility Assessment
3.15. Competitor Market Footprint Matrix
3.16. Key Participants Market Presence (Intensity Map) By Region
4. Global Rare Neurological Disease Treatment Market Analysis and Forecast 2012-2026
4.1. Global Rare Neurological Disease Treatment Market Size and Forecast By Indication, 2012-2026
4.1.1. Alzheimer’s Disease Market Size and Forecast, 2012-2026
4.1.1.1. Revenue (US$ Mn) Comparison, By Region
4.1.1.2. Market Share Comparison, By Region
4.1.1.3. Y-o-Y growth Comparison, By Region
4.1.2. Narcolepsy Market Size and Forecast, 2012-2026
4.1.2.1. Revenue (US$ Mn) Comparison, By Region
4.1.2.2. Market Share Comparison, By Region
4.1.2.3. Y-o-Y growth Comparison, By Region
4.1.3. Multiple Sclerosis Market Size and Forecast, 2012-2026
4.1.3.1. Revenue (US$ Mn) Comparison, By Region
4.1.3.2. Market Share Comparison, By Region
4.1.3.3. Y-o-Y growth Comparison, By Region
4.1.4. Amyotrophic Lateral Sclerosis Market Size and Forecast, 2012-2026
4.1.4.1. Revenue (US$ Mn) Comparison, By Region
4.1.4.2. Market Share Comparison, By Region
4.1.4.3. Y-o-Y growth Comparison, By Region
4.1.5. Other Indications Market Size and Forecast, 2012-2026
4.1.5.1. Revenue (US$ Mn) Comparison, By Region
4.1.5.2. Market Share Comparison, By Region
4.1.5.3. Y-o-Y growth Comparison, By Region
4.2. Global Rare Neurological Disease Treatment Market Size and Forecast By Drug Type, 2012-2026
4.2.1. Biologics Market Size and Forecast, 2012-2026
4.2.1.1. Revenue (US$ Mn) Comparison, By Region
4.2.1.2. Market Share Comparison, By Region
4.2.1.3. Y-o-Y growth Comparison, By Region
4.2.2. Organic Compounds Market Size and Forecast, 2012-2026
4.2.2.1. Revenue (US$ Mn) Comparison, By Region
4.2.2.2. Market Share Comparison, By Region
4.2.2.3. Y-o-Y growth Comparison, By Region
4.3. Global Rare Neurological Disease Treatment Market Size and Forecast By Mode of Administration, 2012-2026
4.3.1. Injectable Market Size and Forecast, 2012-2026
4.3.1.1. Revenue (US$ Mn) Comparison, By Region
4.3.1.2. Market Share Comparison, By Region
4.3.1.3. Y-o-Y growth Comparison, By Region
4.3.2. Oral Market Size and Forecast, 2012-2026
4.3.2.1. Revenue (US$ Mn) Comparison, By Region
4.3.2.2. Market Share Comparison, By Region
4.3.2.3. Y-o-Y growth Comparison, By Region
4.3.3. Others Market Size and Forecast, 2012-2026
4.3.3.1. Revenue (US$ Mn) Comparison, By Region
4.3.3.2. Market Share Comparison, By Region
4.3.3.3. Y-o-Y growth Comparison, By Region
4.4. Global Rare Neurological Disease Treatment Market Size and Forecast By Distribution Channel, 2012-2026
4.4.1. Hospital Pharmacies Market Size and Forecast, 2012-2026
4.4.1.1. Revenue (US$ Mn) Comparison, By Region
4.4.1.2. Market Share Comparison, By Region
4.4.1.3. Y-o-Y growth Comparison, By Region
4.4.2. Retail Pharmacies Market Size and Forecast, 2012-2026
4.4.2.1. Revenue (US$ Mn) Comparison, By Region
4.4.2.2. Market Share Comparison, By Region
4.4.2.3. Y-o-Y growth Comparison, By Region
4.4.3. Online Pharmacies Market Size and Forecast, 2012-2026
4.4.3.1. Revenue (US$ Mn) Comparison, By Region
4.4.3.2. Market Share Comparison, By Region
4.4.3.3. Y-o-Y growth Comparison, By Region
5. North America Rare Neurological Disease Treatment Market Size and Forecast, 2012-2026
5.1. North America Outlook
5.2. North America Parent Market Outlook
5.3. North America Target Market Outlook
5.4. Revenue (US$ Mn) Comparison, By Country
5.4.1. US Market Size and Forecast (US$ Mn), 2012-2026
5.4.2. Canada Market Size and Forecast (US$ Mn), 2012-2026
5.5. Revenue (US$ Mn) Comparison, By Indication
5.6. Revenue (US$ Mn) Comparison, By Drug Type
5.7. Revenue (US$ Mn) Comparison, By Mode of Administration
5.8. Revenue (US$ Mn) Comparison, By Distribution Channel
6. Latin America Rare Neurological Disease Treatment Market Size and Forecast, 2012-2026
6.1. Latin America Outlook
6.2. Latin America Parent Market Outlook
6.3. Latin America Target Market Outlook
6.4. Revenue (US$ Mn) Comparison, By Country
6.4.1. Brazil Market Size and Forecast (US$ Mn), 2012-2026
6.4.2. Mexico Market Size and Forecast (US$ Mn), 2012-2026
6.4.3. Rest of Latin America Market Size and Forecast (US$ Mn), 2012-2026
6.5. Revenue (US$ Mn) Comparison, By Indication
6.6. Revenue (US$ Mn) Comparison, By Drug Type
6.7. Revenue (US$ Mn) Comparison, By Mode of Administration
6.8. Revenue (US$ Mn) Comparison, By Distribution Channel
7. Europe Rare Neurological Disease Treatment Market Size and Forecast, 2012-2026
7.1. Europe Outlook
7.2. Europe Parent Market Outlook
7.3. Europe Target Market Outlook
7.4. Revenue (US$ Mn) Comparison, By Country
7.4.1. Germany Market Size and Forecast (US$ Mn), 2012-2026
7.4.2. UK Market Size and Forecast (US$ Mn), 2012-2026
7.4.3. France Market Size and Forecast (US$ Mn), 2012-2026
7.4.4. Spain Market Size and Forecast (US$ Mn), 2012-2026
7.4.5. Italy Market Size and Forecast (US$ Mn), 2012-2026
7.4.6. Rest of Europe Market Size and Forecast (US$ Mn), 2012-2026
7.5. Revenue (US$ Mn) Comparison, By Indication
7.6. Revenue (US$ Mn) Comparison, By Drug Type
7.7. Revenue (US$ Mn) Comparison, By Mode of Administration
7.8. Revenue (US$ Mn) Comparison, By Distribution Channel
8. Japan Rare Neurological Disease Treatment Market Size and Forecast, 2012-2026
8.1. Japan Outlook
8.2. Japan Parent Market Outlook
8.3. Japan Target Market Outlook
8.4. Japan Market Size and Forecast (US$ Mn), 2012-2026
8.5. Revenue (US$ Mn) Comparison, By Indication
8.6. Revenue (US$ Mn) Comparison, By Drug Type
8.7. Revenue (US$ Mn) Comparison, By Mode of Administration
8.8. Revenue (US$ Mn) Comparison, By Distribution Channel
9. APEJ Rare Neurological Disease Treatment Market Size and Forecast, 2012-2026
9.1. APEJ Outlook
9.2. APEJ Parent Market Outlook
9.3. APEJ Target Market Outlook
9.4. Revenue (US$ Mn) Comparison, By Country
9.4.1. China Market Size and Forecast (US$ Mn), 2012-2026
9.4.2. India Market Size and Forecast (US$ Mn), 2012-2026
9.4.3. Thailand Market Size and Forecast (US$ Mn), 2012-2026
9.4.4. Singapore Market Size and Forecast (US$ Mn), 2012-2026
9.4.5. Australia Market Size and Forecast (US$ Mn), 2012-2026
9.4.6. Rest of APEJ Market Size and Forecast (US$ Mn), 2012-2026
9.5. Revenue (US$ Mn) Comparison, By Indication
9.6. Revenue (US$ Mn) Comparison, By Drug Type
9.7. Revenue (US$ Mn) Comparison, By Mode of Administration
9.8. Revenue (US$ Mn) Comparison, By Distribution Channel
10. MEA Rare Neurological Disease Treatment Market Size and Forecast, 2012-2026
10.1. MEA Outlook
10.2. MEA Parent Market Outlook
10.3. MEA Target Market Outlook
10.4. Revenue (US$ Mn) Comparison, By Country
10.4.1. GCC Countries Market Size and Forecast (US$ Mn), 2012-2026
10.4.2. South Africa Market Size and Forecast (US$ Mn), 2012-2026
10.4.3. Nigeria Market Size and Forecast (US$ Mn), 2012-2026
10.4.4. Rest of MEA Market Size and Forecast (US$ Mn), 2012-2026
10.5. Revenue (US$ Mn) Comparison, By Indication
10.6. Revenue (US$ Mn) Comparison, By Drug Type
10.7. Revenue (US$ Mn) Comparison, By Mode of Administration
10.8. Revenue (US$ Mn) Comparison, By Distribution Channel
11. Global Rare Neurological Disease Treatment Market Company Share, Competition Landscape and Company Profiles
11.1. Global Rare Neurological Disease Treatment Market Company Share Analysis
11.2. Global Rare Neurological Disease Treatment Market Competition Landscape
11.3. Global Rare Neurological Disease Treatment Market Company Profiles
11.3.1. Pfizer Inc.
11.3.2. Allergan Plc
11.3.3. Novartis AG
11.3.4. Bayer Aktiengesellschaft
11.3.5. Medtronic Plc
11.3.6. Sanofi
11.3.7. Johnson & Johnson
11.3.8. Teva Pharmaceutical Industries Limited
11.3.9. Jazz Pharmaceuticals
11.3.10. EMD Serono, Inc.
12. Key Takeaways
13. Research Methodology
14. Disclaimer
Rare Neurological Disease Treatment Market Reports - List of Tables
TABLE 1 Global Rare Neurological Disease Treatment Market Value (US$ Mn), 2012-2017
TABLE 2 Global Rare Neurological Disease Treatment Market Value (US$ Mn), 2018-2026
TABLE 3 Global Rare Neurological Disease Treatment Market Value (US$ Mn) and Y-o-Y, 2017-2026
TABLE 4 Global Alzheimer’s Disease Segment Value (US$ Mn), By Region 2012-2017
TABLE 5 Global Alzheimer’s Disease Segment Value (US$ Mn), By Region 2018-2026
TABLE 6 Global Alzheimer’s Disease Segment Market Share, By Region 2012-2017
TABLE 7 Global Alzheimer’s Disease Segment Market Share, By Region 2018-2026
TABLE 8 Global Alzheimer’s Disease Segment Y-o-Y, By Region 2017-2026
TABLE 9 Global Narcolepsy Segment Value (US$ Mn), By Region 2012-2017
TABLE 10 Global Narcolepsy Segment Value (US$ Mn), By Region 2018-2026
TABLE 11 Global Narcolepsy Segment Market Share, By Region 2012-2017
TABLE 12 Global Narcolepsy Segment Market Share, By Region 2018-2026
TABLE 13 Global Narcolepsy Segment Y-o-Y, By Region 2017-2026
TABLE 14 Global Multiple Sclerosis Segment Value (US$ Mn), By Region 2012-2017
TABLE 15 Global Multiple Sclerosis Segment Value (US$ Mn), By Region 2018-2026
TABLE 16 Global Multiple Sclerosis Segment Market Share, By Region 2012-2017
TABLE 17 Global Multiple Sclerosis Segment Market Share, By Region 2018-2026
TABLE 18 Global Multiple Sclerosis Segment Y-o-Y, By Region 2017-2026
TABLE 19 Global Amyotrophic Lateral Sclerosis Segment Value (US$ Mn), By Region 2012-2017
TABLE 20 Global Amyotrophic Lateral Sclerosis Segment Value (US$ Mn), By Region 2018-2026
TABLE 21 Global Amyotrophic Lateral Sclerosis Segment Market Share, By Region 2012-2017
TABLE 22 Global Amyotrophic Lateral Sclerosis Segment Market Share, By Region 2018-2026
TABLE 23 Global Amyotrophic Lateral Sclerosis Segment Y-o-Y, By Region 2017-2026
TABLE 24 Global Other Indications Segment Value (US$ Mn), By Region 2012-2017
TABLE 25 Global Other Indications Segment Value (US$ Mn), By Region 2018-2026
TABLE 26 Global Other Indications Segment Market Share, By Region 2012-2017
TABLE 27 Global Other Indications Segment Market Share, By Region 2018-2026
TABLE 28 Global Other Indications Segment Y-o-Y, By Region 2017-2026
TABLE 29 Global Biologics Segment Value (US$ Mn), By Region 2012-2017
TABLE 30 Global Biologics Segment Value (US$ Mn), By Region 2018-2026
TABLE 31 Global Biologics Segment Market Share, By Region 2012-2017
TABLE 32 Global Biologics Segment Market Share, By Region 2018-2026
TABLE 33 Global Biologics Segment Y-o-Y, By Region 2017-2026
TABLE 34 Global Organic Compounds Segment Value (US$ Mn), By Region 2012-2017
TABLE 35 Global Organic Compounds Segment Value (US$ Mn), By Region 2018-2026
TABLE 36 Global Organic Compounds Segment Market Share, By Region 2012-2017
TABLE 37 Global Organic Compounds Segment Market Share, By Region 2018-2026
TABLE 38 Global Organic Compounds Segment Y-o-Y, By Region 2017-2026
TABLE 39 Global Injectables Segment Value (US$ Mn), By Region 2012-2017
TABLE 40 Global Injectables Segment Value (US$ Mn), By Region 2018-2026
TABLE 41 Global Injectables Segment Market Share, By Region 2012-2017
TABLE 42 Global Injectables Segment Market Share, By Region 2018-2026
TABLE 43 Global Injectables Segment Y-o-Y, By Region 2017-2026
TABLE 44 Global Oral Segment Value (US$ Mn), By Region 2012-2017
TABLE 45 Global Oral Segment Value (US$ Mn), By Region 2018-2026
TABLE 46 Global Oral Segment Market Share, By Region 2012-2017
TABLE 47 Global Oral Segment Market Share, By Region 2018-2026
TABLE 48 Global Oral Segment Y-o-Y, By Region 2017-2026
TABLE 49 Global Others Segment Value (US$ Mn), By Region 2012-2017
TABLE 50 Global Others Segment Value (US$ Mn), By Region 2018-2026
TABLE 51 Global Others Segment Market Share, By Region 2012-2017
TABLE 52 Global Others Segment Market Share, By Region 2018-2026
TABLE 53 Global Others Segment Y-o-Y, By Region 2017-2026
TABLE 54 Global Hospital Pharmacies Segment Value (US$ Mn), By Region 2012-2017
TABLE 55 Global Hospital Pharmacies Segment Value (US$ Mn), By Region 2018-2026
TABLE 56 Global Hospital Pharmacies Segment Market Share, By Region 2012-2017
TABLE 57 Global Hospital Pharmacies Segment Market Share, By Region 2018-2026
TABLE 58 Global Hospital Pharmacies Segment Y-o-Y, By Region 2017-2026
TABLE 59 Global Retail Pharmacies Segment Value (US$ Mn), By Region 2012-2017
TABLE 60 Global Retail Pharmacies Segment Value (US$ Mn), By Region 2018-2026
TABLE 61 Global Retail Pharmacies Segment Market Share, By Region 2012-2017
TABLE 62 Global Retail Pharmacies Segment Market Share, By Region 2018-2026
TABLE 63 Global Retail Pharmacies Segment Y-o-Y, By Region 2017-2026
TABLE 64 Global Online Pharmacies Segment Value (US$ Mn), By Region 2012-2017
TABLE 65 Global Online Pharmacies Segment Value (US$ Mn), By Region 2018-2026
TABLE 66 Global Online Pharmacies Segment Market Share, By Region 2012-2017
TABLE 67 Global Online Pharmacies Segment Market Share, By Region 2018-2026
TABLE 68 Global Online Pharmacies Segment Y-o-Y, By Region 2017-2026
TABLE 69 North America Rare Neurological Disease Treatment Market Value (US$ Mn), By Country 2012-2017
TABLE 70 North America Rare Neurological Disease Treatment Market Value (US$ Mn), By Country 2018-2026
TABLE 71 North America Rare Neurological Disease Treatment Market Value (US$ Mn), By Indication 2012-2017
TABLE 72 North America Rare Neurological Disease Treatment Market Value (US$ Mn), By Indication 2018-2026
TABLE 73 North America Rare Neurological Disease Treatment Market Value (US$ Mn), By Drug Type 2012-2017
TABLE 74 North America Rare Neurological Disease Treatment Market Value (US$ Mn), By Drug Type 2018-2026
TABLE 75 North America Rare Neurological Disease Treatment Market Value (US$ Mn), By Mode of Administration 2012-2017
TABLE 76 North America Rare Neurological Disease Treatment Market Value (US$ Mn), By Mode of Administration 2018-2026
TABLE 77 North America Rare Neurological Disease Treatment Market Value (US$ Mn), By Distribution Channel 2012-2017
TABLE 78 North America Rare Neurological Disease Treatment Market Value (US$ Mn), By Distribution Channel 2018-2026
TABLE 79 Latin America Rare Neurological Disease Treatment Market Value (US$ Mn), By Country 2012-2017
TABLE 80 Latin America Rare Neurological Disease Treatment Market Value (US$ Mn), By Country 2018-2026
TABLE 81 Latin America Rare Neurological Disease Treatment Market Value (US$ Mn), By Indication 2012-2017
TABLE 82 Latin America Rare Neurological Disease Treatment Market Value (US$ Mn), By Indication 2018-2026
TABLE 83 Latin America Rare Neurological Disease Treatment Market Value (US$ Mn), By Drug Type 2012-2017
TABLE 84 Latin America Rare Neurological Disease Treatment Market Value (US$ Mn), By Drug Type 2018-2026
TABLE 85 Latin America Rare Neurological Disease Treatment Market Value (US$ Mn), By Mode of Administration 2012-2017
TABLE 86 Latin America Rare Neurological Disease Treatment Market Value (US$ Mn), By Mode of Administration 2018-2026
TABLE 87 Latin America Rare Neurological Disease Treatment Market Value (US$ Mn), By Distribution Channel 2012-2017
TABLE 88 Latin America Rare Neurological Disease Treatment Market Value (US$ Mn), By Distribution Channel 2018-2026
TABLE 89 Europe Rare Neurological Disease Treatment Market Value (US$ Mn), By Country 2012-2017
TABLE 90 Europe Rare Neurological Disease Treatment Market Value (US$ Mn), By Country 2018-2026
TABLE 91 Europe Rare Neurological Disease Treatment Market Value (US$ Mn), By Indication 2012-2017
TABLE 92 Europe Rare Neurological Disease Treatment Market Value (US$ Mn), By Indication 2018-2026
TABLE 93 Europe Rare Neurological Disease Treatment Market Value (US$ Mn), By Drug Type 2012-2017
TABLE 94 Europe Rare Neurological Disease Treatment Market Value (US$ Mn), By Drug Type 2018-2026
TABLE 95 Europe Rare Neurological Disease Treatment Market Value (US$ Mn), By Mode of Administration 2012-2017
TABLE 96 Europe Rare Neurological Disease Treatment Market Value (US$ Mn), By Mode of Administration 2018-2026
TABLE 97 Europe Rare Neurological Disease Treatment Market Value (US$ Mn), By Distribution Channel 2012-2017
TABLE 98 Europe Rare Neurological Disease Treatment Market Value (US$ Mn), By Distribution Channel 2018-2026
TABLE 99 Japan Rare Neurological Disease Treatment Market Value (US$ Mn), By Country 2012-2017
TABLE 100 Japan Rare Neurological Disease Treatment Market Value (US$ Mn), By Country 2018-2026
TABLE 101 Japan Rare Neurological Disease Treatment Market Value (US$ Mn), By Indication 2012-2017
TABLE 102 Japan Rare Neurological Disease Treatment Market Value (US$ Mn), By Indication 2018-2026
TABLE 103 Japan Rare Neurological Disease Treatment Market Value (US$ Mn), By Drug Type 2012-2017
TABLE 104 Japan Rare Neurological Disease Treatment Market Value (US$ Mn), By Drug Type 2018-2026
TABLE 105 Japan Rare Neurological Disease Treatment Market Value (US$ Mn), By Mode of Administration 2012-2017
TABLE 106 Japan Rare Neurological Disease Treatment Market Value (US$ Mn), By Mode of Administration 2018-2026
TABLE 107 Japan Rare Neurological Disease Treatment Market Value (US$ Mn), By Distribution Channel 2012-2017
TABLE 108 Japan Rare Neurological Disease Treatment Market Value (US$ Mn), By Distribution Channel 2018-2026
TABLE 109 APEJ Rare Neurological Disease Treatment Market Value (US$ Mn), By Country 2012-2017
TABLE 110 APEJ Rare Neurological Disease Treatment Market Value (US$ Mn), By Country 2018-2026
TABLE 111 APEJ Rare Neurological Disease Treatment Market Value (US$ Mn), By Indication 2012-2017
TABLE 112 APEJ Rare Neurological Disease Treatment Market Value (US$ Mn), By Indication 2018-2026
TABLE 113 APEJ Rare Neurological Disease Treatment Market Value (US$ Mn), By Drug Type 2012-2017
TABLE 114 APEJ Rare Neurological Disease Treatment Market Value (US$ Mn), By Drug Type 2018-2026
TABLE 115 APEJ Rare Neurological Disease Treatment Market Value (US$ Mn), By Mode of Administration 2012-2017
TABLE 116 APEJ Rare Neurological Disease Treatment Market Value (US$ Mn), By Mode of Administration 2018-2026
TABLE 117 APEJ Rare Neurological Disease Treatment Market Value (US$ Mn), By Distribution Channel 2012-2017
TABLE 118 APEJ Rare Neurological Disease Treatment Market Value (US$ Mn), By Distribution Channel 2018-2026
TABLE 119 MEA Rare Neurological Disease Treatment Market Value (US$ Mn), By Country 2012-2017
TABLE 120 MEA Rare Neurological Disease Treatment Market Value (US$ Mn), By Country 2018-2026
TABLE 121 MEA Rare Neurological Disease Treatment Market Value (US$ Mn), By Indication 2012-2017
TABLE 122 MEA Rare Neurological Disease Treatment Market Value (US$ Mn), By Indication 2018-2026
TABLE 123 MEA Rare Neurological Disease Treatment Market Value (US$ Mn), By Drug Type 2012-2017
TABLE 124 MEA Rare Neurological Disease Treatment Market Value (US$ Mn), By Drug Type 2018-2026
TABLE 125 MEA Rare Neurological Disease Treatment Market Value (US$ Mn), By Mode of Administration 2012-2017
TABLE 126 MEA Rare Neurological Disease Treatment Market Value (US$ Mn), By Mode of Administration 2018-2026
TABLE 127 MEA Rare Neurological Disease Treatment Market Value (US$ Mn), By Distribution Channel 2012-2017
TABLE 128 MEA Rare Neurological Disease Treatment Market Value (US$ Mn), By Distribution Channel 2018-2026
Rare Neurological Disease Treatment Market Reports - List of Figures
FIG. 1 Global Rare Neurological Disease Treatment Market Value (US$ Mn), 2012-2017
FIG. 2 Global Rare Neurological Disease Treatment Market Value (US$ Mn) Forecast, 2018-2026
FIG. 3 Global Rare Neurological Disease Treatment Market Value (US$ Mn) and Y-o-Y, 2017-2026
FIG. 4 Global Alzheimer’s Disease Segment Market Value (US$ Mn) By Region, 2012-2017
FIG. 5 Global Alzheimer’s Disease Segment Market Value (US$ Mn) By Region, 2018-2026
FIG. 6 Global Alzheimer’s Disease Segment Y-o-Y Growth Rate, By Region, 2017-2026
FIG. 7 Global Narcolepsy Segment Market Value (US$ Mn) By Region, 2012-2017
FIG. 8 Global Narcolepsy Segment Market Value (US$ Mn) By Region, 2018-2026
FIG. 9 Global Narcolepsy Segment Y-o-Y Growth Rate, By Region, 2017-2026
FIG. 10 Global Multiple Sclerosis Segment Market Value (US$ Mn) By Region, 2012-2017
FIG. 11 Global Multiple Sclerosis Segment Market Value (US$ Mn) By Region, 2018-2026
FIG. 12 Global Multiple Sclerosis Segment Y-o-Y Growth Rate, By Region, 2017-2026
FIG. 13 Global Amyotrophic Lateral Sclerosis Segment Market Value (US$ Mn) By Region, 2012-2017
FIG. 14 Global Amyotrophic Lateral Sclerosis Segment Market Value (US$ Mn) By Region, 2018-2026
FIG. 15 Global Amyotrophic Lateral Sclerosis Segment Y-o-Y Growth Rate, By Region, 2017-2026
FIG. 16 Global Other Indications Segment Market Value (US$ Mn) By Region, 2012-2017
FIG. 17 Global Other Indications Segment Market Value (US$ Mn) By Region, 2018-2026
FIG. 18 Global Other Indications Segment Y-o-Y Growth Rate, By Region, 2017-2026
FIG. 19 Global Biologics Segment Market Value (US$ Mn) By Region, 2012-2017
FIG. 20 Global Biologics Segment Market Value (US$ Mn) By Region, 2018-2026
FIG. 21 Global Biologics Segment Y-o-Y Growth Rate, By Region, 2017-2026
FIG. 22 Global Organic Compounds Segment Market Value (US$ Mn) By Region, 2012-2017
FIG. 23 Global Organic Compounds Segment Market Value (US$ Mn) By Region, 2018-2026
FIG. 24 Global Organic Compounds Segment Y-o-Y Growth Rate, By Region, 2017-2026
FIG. 25 Global Injectables Segment Market Value (US$ Mn) By Region, 2012-2017
FIG. 26 Global Injectables Segment Market Value (US$ Mn) By Region, 2018-2026
FIG. 27 Global Injectables Segment Y-o-Y Growth Rate, By Region, 2017-2026
FIG. 28 Global Oral Segment Market Value (US$ Mn) By Region, 2012-2017
FIG. 29 Global Oral Segment Market Value (US$ Mn) By Region, 2018-2026
FIG. 30 Global Oral Segment Y-o-Y Growth Rate, By Region, 2017-2026
FIG. 31 Global Others Segment Market Value (US$ Mn) By Region, 2012-2017
FIG. 32 Global Others Segment Market Value (US$ Mn) By Region, 2018-2026
FIG. 33 Global Others Segment Y-o-Y Growth Rate, By Region, 2017-2026
FIG. 34 Global Hospital Pharmacies Segment Market Value (US$ Mn) By Region, 2012-2017
FIG. 35 Global Hospital Pharmacies Segment Market Value (US$ Mn) By Region, 2018-2026
FIG. 36 Global Hospital Pharmacies Segment Y-o-Y Growth Rate, By Region, 2017-2026
FIG. 37 Global Retail Pharmacies Segment Market Value (US$ Mn) By Region, 2012-2017
FIG. 38 Global Retail Pharmacies Segment Market Value (US$ Mn) By Region, 2018-2026
FIG. 39 Global Retail Pharmacies Segment Y-o-Y Growth Rate, By Region, 2017-2026
FIG. 40 Global Online Pharmacies Segment Market Value (US$ Mn) By Region, 2012-2017
FIG. 41 Global Online Pharmacies Segment Market Value (US$ Mn) By Region, 2018-2026
FIG. 42 Global Online Pharmacies Segment Y-o-Y Growth Rate, By Region, 2017-2026
FIG. 43 North America Rare Neurological Disease Treatment Market Value (US$ Mn), By Country 2012-2017
FIG. 44 North America Rare Neurological Disease Treatment Market Value (US$ Mn), By Country 2018-2026
FIG. 45 North America Rare Neurological Disease Treatment Market Value (US$ Mn), By Indication 2012-2017
FIG. 46 North America Rare Neurological Disease Treatment Market Value (US$ Mn), By Indication 2018-2026
FIG. 47 North America Rare Neurological Disease Treatment Market Value (US$ Mn), By Drug Type 2012-2017
FIG. 48 North America Rare Neurological Disease Treatment Market Value (US$ Mn), By Drug Type 2018-2026
FIG. 49 North America Rare Neurological Disease Treatment Market Value (US$ Mn), By Mode of Administration 2012-2017
FIG. 50 North America Rare Neurological Disease Treatment Market Value (US$ Mn), By Mode of Administration 2018-2026
FIG. 51 North America Rare Neurological Disease Treatment Market Value (US$ Mn), By Distribution Channel 2012-2017
FIG. 52 North America Rare Neurological Disease Treatment Market Value (US$ Mn), By Distribution Channel 2018-2026
FIG. 53 Latin America Rare Neurological Disease Treatment Market Value (US$ Mn), By Country 2012-2017
FIG. 54 Latin America Rare Neurological Disease Treatment Market Value (US$ Mn), By Country 2018-2026
FIG. 55 Latin America Rare Neurological Disease Treatment Market Value (US$ Mn), By Indication 2012-2017
FIG. 56 Latin America Rare Neurological Disease Treatment Market Value (US$ Mn), By Indication 2018-2026
FIG. 57 Latin America Rare Neurological Disease Treatment Market Value (US$ Mn), By Drug Type 2012-2017
FIG. 58 Latin America Rare Neurological Disease Treatment Market Value (US$ Mn), By Drug Type 2018-2026
FIG. 59 Latin America Rare Neurological Disease Treatment Market Value (US$ Mn), By Mode of Administration 2012-2017
FIG. 60 Latin America Rare Neurological Disease Treatment Market Value (US$ Mn), By Mode of Administration 2018-2026
FIG. 61 Latin America Rare Neurological Disease Treatment Market Value (US$ Mn), By Distribution Channel 2012-2017
FIG. 62 Latin America Rare Neurological Disease Treatment Market Value (US$ Mn), By Distribution Channel 2018-2026
FIG. 63 Europe Rare Neurological Disease Treatment Market Value (US$ Mn), By Country 2012-2017
FIG. 64 Europe Rare Neurological Disease Treatment Market Value (US$ Mn), By Country 2018-2026
FIG. 65 Europe Rare Neurological Disease Treatment Market Value (US$ Mn), By Indication 2012-2017
FIG. 66 Europe Rare Neurological Disease Treatment Market Value (US$ Mn), By Indication 2018-2026
FIG. 67 Europe Rare Neurological Disease Treatment Market Value (US$ Mn), By Drug Type 2012-2017
FIG. 68 Europe Rare Neurological Disease Treatment Market Value (US$ Mn), By Drug Type 2018-2026
FIG. 69 Europe Rare Neurological Disease Treatment Market Value (US$ Mn), By Mode of Administration 2012-2017
FIG. 70 Europe Rare Neurological Disease Treatment Market Value (US$ Mn), By Mode of Administration 2018-2026
FIG. 71 Europe Rare Neurological Disease Treatment Market Value (US$ Mn), By Distribution Channel 2012-2017
FIG. 72 Europe Rare Neurological Disease Treatment Market Value (US$ Mn), By Distribution Channel 2018-2026
FIG. 73 Japan Rare Neurological Disease Treatment Market Value (US$ Mn), By Country 2012-2017
FIG. 74 Japan Rare Neurological Disease Treatment Market Value (US$ Mn), By Country 2018-2026
FIG. 75 Japan Rare Neurological Disease Treatment Market Value (US$ Mn), By Indication 2012-2017
FIG. 76 Japan Rare Neurological Disease Treatment Market Value (US$ Mn), By Indication 2018-2026
FIG. 77 Japan Rare Neurological Disease Treatment Market Value (US$ Mn), By Mode of Administration 2012-2017
FIG. 78 Japan Rare Neurological Disease Treatment Market Value (US$ Mn), By Drug Type 2018-2026
FIG. 79 Japan Rare Neurological Disease Treatment Market Value (US$ Mn), By Mode of Administration 2012-2017
FIG. 80 Japan Rare Neurological Disease Treatment Market Value (US$ Mn), By Mode of Administration 2018-2026
FIG. 81 Japan Rare Neurological Disease Treatment Market Value (US$ Mn), By Distribution Channel 2012-2017
FIG. 82 Japan Rare Neurological Disease Treatment Market Value (US$ Mn), By Distribution Channel 2018-2026
FIG. 83 APEJ Rare Neurological Disease Treatment Market Value (US$ Mn), By Country 2012-2017
FIG. 84 APEJ Rare Neurological Disease Treatment Market Value (US$ Mn), By Country 2018-2026
FIG. 85 APEJ Rare Neurological Disease Treatment Market Value (US$ Mn), By Indication 2012-2017
FIG. 86 APEJ Rare Neurological Disease Treatment Market Value (US$ Mn), By Indication 2018-2026
FIG. 87 APEJ Rare Neurological Disease Treatment Market Value (US$ Mn), By Drug Type 2012-2017
FIG. 88 APEJ Rare Neurological Disease Treatment Market Value (US$ Mn), By Drug Type 2018-2026
FIG. 89 APEJ Rare Neurological Disease Treatment Market Value (US$ Mn), By Mode of Administration 2012-2017
FIG. 90 APEJ Rare Neurological Disease Treatment Market Value (US$ Mn), By Mode of Administration 2018-2026
FIG. 91 APEJ Rare Neurological Disease Treatment Market Value (US$ Mn), By Distribution Channel 2012-2017
FIG. 92 APEJ Rare Neurological Disease Treatment Market Value (US$ Mn), By Distribution Channel 2018-2026
FIG. 93 MEA Rare Neurological Disease Treatment Market Value (US$ Mn), By Country 2012-2017
FIG. 94 MEA Rare Neurological Disease Treatment Market Value (US$ Mn), By Country 2018-2026
FIG. 95 MEA Rare Neurological Disease Treatment Market Value (US$ Mn), By Indication 2012-2017
FIG. 96 MEA Rare Neurological Disease Treatment Market Value (US$ Mn), By Indication 2018-2026
FIG. 97 MEA Rare Neurological Disease Treatment Market Value (US$ Mn), By Drug Type 2012-2017
FIG. 98 MEA Rare Neurological Disease Treatment Market Value (US$ Mn), By Drug Type 2018-2026
FIG. 99 MEA Rare Neurological Disease Treatment Market Value (US$ Mn), By Mode of Administration 2012-2017
FIG. 100 MEA Rare Neurological Disease Treatment Market Value (US$ Mn), By Mode of Administration 2018-2026
FIG. 101 MEA Rare Neurological Disease Treatment Market Value (US$ Mn), By Distribution Channel 2012-2017
FIG. 102 MEA Rare Neurological Disease Treatment Market Value (US$ Mn), By Distribution Channel 2018-2026